CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

DISEASE CHARACTERISTICS: Histologically confirmed refractory solid tumor and/or lymphoma No brain metastases or primary CNS malignancies PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: More than 3 months Hematopoietic: Granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin normal ALT and AST less than 2.5 times normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: No unstable or newly diagnosed angina pectoris No myocardial infarction within the past 6 months No New York Heart Association class II, III, or IV congestive heart failure Pulmonary: No chronic obstructive lung disease requiring oxygen therapy Other: No uncontrolled seizures No concurrent acute critical illness No serious untreated infection Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 2 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or carboplatin) No concurrent cytotoxic chemotherapy Endocrine therapy: At least 4 weeks since prior hormonal therapy Concurrent luteinizing hormone-releasing hormone agonist required in patients with prostate cancer unless prior orchiectomy has been performed Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: See Endocrine therapy Prior surgery allowed Other: Recovered from prior therapy No concurrent anticonvulsants (e.g., phenobarbital, phenytoin, or carbamazepine) No concurrent rifampin No concurrent grapefruit juice